ABSTRACT. The presence of concomitant psoriatic arthritis (PsA) directly affects the treatment decisions dermatologists may make as they manage their patients' psoriasis (PsO). Because the prevalence of PsA increases with PsO duration, it is important to regularly screen for signs and symptoms of PsA.
According to current guidelines, mild psoriasis (PsO) can potentially be managed using topical therapies, while moderate-to-severe PsO necessitates phototherapy or systemic therapy in combination with topicals 1 . If the patient has coexisting psoriatic arthritis (PsA), a systemic therapy may be needed even if the patient exhibits only mild PsO 2 . Further, PsA may involve peripheral joints, the axial skeleton, tendons, and entheses 3 , all of which respond differently to drugs currently available 4 . The presence and type of PsA, therefore, may directly influence the dermatologist's treat ment decision. This is true from a medical as well as from a regulatory point of view, as not every drug available to treat PsO is approved for the treatment of both PsO and PsA, and vice versa.
The Role of Dermatologists in Screening for
PsA Along with the difficulties described above, dermatologists need to screen for PsA symptoms for at least 3 additional reasons 5 : 1. PsA is more common than previously thought. While older textbooks cite PsA in 6-8% of patients with PsO, more recent epidemiologic and clinical studies suggest numbers on the order of 15-30%. 2. PsA is more serious than previously thought. Although it has sometimes been nicknamed "the little sister of rheumatoid arthritis," it is now clear that about 50% of patients with PsA have a chronic-progressive disease course. 3. Even a relatively short delay in diagnosis and adequate treatment of PsA is associated with a worse longterm outcome 6 .
Thus, screening for PsA to ensure early diagnosis and treatment is a high priority. And dermatologists are in a position to be "sentinels," because in the majority of cases, PsA symptoms manifest after the onset of PsO 3 .
Who and How to Screen
Although there is a trend toward a higher prevalence of PsA among patients with severe PsO, the prevalence of PsA among patients with mild PsO is still high, thus necessitating inclusion of every patient with PsO in the dermatologists' screening efforts. The likelihood of PsA is particularly high if the patient has PsO of the scalp or nails, or has perianal or intertriginous manifestations 7 .
Given the clinical heterogeneity of PsA, it is difficult for nonrheumatologists to establish this diagnosis. Numerous groups have developed screening questionnaires as potential tools for this purpose, e.g., the Psoriatic Arthritis Screening and Evaluation (PASE) questionnaire, the Toronto Psoriatic Arthritis Screening (ToPAS) questionnaire, and the Psoriasis Epidemiology Screening Tool (PEST). While initial reports of these questionnaires suggested good sensitivities, a subsequent publication reported much lower ones 8 . In a recent head-to-head comparison study, sensitivity values of about 75% were found 9 . Such questionnaires -with reasonably good but not excellent sensitivity -might therefore be considered helpful for screening purposes, but should not replace careful physical examination and additional questions.
How to Organize the Cooperation Between Dermatologists and Rheumatologists
It is evident that screening for PsA is an important task for dermatologists, but it might quickly become time-consuming once actions beyond the evaluation of questionnaires are involved. The need to effectively and efficiently identify potential PsA patients for referral to a rheumatologist for diagnosis where required and to organize cooperation between dermatologists and rheumatologists for patients with PsA becomes even more urgent to ensure these patients are appropriately treated and monitored to improve longterm outcomes. Achieving this cooperation depends to a large extent on the resources made available by the respective healthcare system, as highlighted by a comparison between Germany and Switzerland.
Cooperation Between Dermatologists and Rheumatologists in Germany and Switzerland
In Germany, numerous initiatives over the last decade were meant to enable dermatologists to screen for and to a certain extent, to treat PsA. These included joint symposia of dermatologists and rheumatologists on the management of PsA as well as workshops focusing on the early diagnosis of PsA by dermatologists.
In Switzerland, a recent Delphi exercise in a group of 8 dermatologists and 8 rheumatologists from secondary and tertiary care centers yielded different answers from the 2 professions (Table 1) 10 . The group did agree on the importance of screening patients with PsO for signs and symptoms of PsA, as well as the potential for dermatologists to serve as sentinels in this regard. Moreover, they agreed on the goal to initiate an effective early treatment to prevent structural damage and functional loss.
On the other hand, the rheumatologists discouraged a more active role for dermatologists. For example, the group agreed that nonrheumatologists should not order imaging as part of the diagnostic investigations, and initiation of a therapy with disease-modifying antirheumatic drugs such as methotrexate or biologics should be discussed with a rheumatologist.
With regard to the envisioned cooperative models, these differences may be explained at least in part by the differences in the respective healthcare systems despite numerous similarities 11 . In Germany, there are about 4000 dermatologists and 400 rheumatologists for 80 million people; in Switzerland, the respective numbers are 400, 400, and 8 million. Thus, German dermatologists need to serve as "filters" to protect the time of rheumatologists, while rheumatologists in Switzerland probably have time to see patients with PsA, those with other inflammatory joint diseases, and those with noninflammatory disorders such as osteoarthritis. Hence, the respective roles of dermatologists might be labeled "gatekeeper" in Germany, but "pilot" in Switzerland.
Perspectives
While the importance of PsO as a global health problem has been widely accepted and underlined by a recent resolution of the World Health Organization, awareness of the importance and effect of PsA must still be fully established. Routine screening for PsA among patients with PsO is not widely practiced, and the available tools must be optimized further. Rheumatologists should confirm the diagnosis of PsA suspected by nonrheumatologists 92 Introduction of DMARD treatment by dermatologists needs to be discussed with the rheumatologist 83 Dermatologists and rheumatologists need to jointly follow PsA patients 100 Proven efficacy in PsO and PsA is a substantial advantage for a drug to be used in treating patients with PsO and/or PsA 84 The treatment goal should be "minimal residual disease" 100 Treatment response must be assessed regularly (about every 3 months) and treatment must be adapted accordingly 100 DMARD: disease-modifying antirheumatic drug; PsA: psoriatic arthritis; PsO: psoriasis.
